Skip to main content
Erschienen in: Notfall + Rettungsmedizin 3/2011

01.04.2011 | CME Weiterbildung · Zertifizierte Fortbildung

Kardiale Biomarker in der Notfallmedizin

verfasst von: Prof. Dr. M. Möckel, J. Searle, O. Danne, C. Müller

Erschienen in: Notfall + Rettungsmedizin | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Evaluierung von Patienten mit Herzinfarktverdacht ist eine der größten Herausforderungen in der Notfallmedizin. Biochemische Marker spielen hier eine herausragende Rolle und werden häufig bereits präklinisch oder früh in der innerklinischen Notfallmedizin eingesetzt. Aktuell werden die kardialen Troponine T + I und vereinzelt natriuretische Peptide verwendet. Als kardiospezifischste Biomarker werden die kardialen Troponine in den Richtlinien eindeutig als bevorzugte Marker für die Diagnostik und Risikostratifizierung von Patienten mit akutem Koronarsyndrom angegeben. Da die Troponine als Marker myokardialen Zelluntergangs ausschließlich stattgehabte Gewebeschädigung anzeigen und erst mit Zeitverzögerung nach Symptombeginn im Blut messbar sind, besteht der Bedarf nach einer neuen Generation von Markern und Assays, die frühzeitig vor Eintritt einer irreversiblen Schädigung Risikopatienten identifizieren und einer Therapie zugänglich machen. Diese Übersichtsarbeit befasst sich mit einer Reihe neuer kardialer Biomarker, die aufgrund ihres Pathomechanismus oder ihrer Assayeigenschaften versprechen, diesen Bedarf zukünftig abzudecken und in den Klinikalltag integrierbar zu sein. Dazu gehören die hochsensitiven kardialen Troponine, Copeptin, „h-fatty acid binding protein“, Cholin, natriuretische Peptide und die lipoproteinassoziierte Phospholipase A2.
Literatur
1.
Zurück zum Zitat (n a) (2000) Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 21:1502–1513 (n a) (2000) Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 21:1502–1513
2.
Zurück zum Zitat Anand IS, Fisher LD, Chiang YT et al (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:1278–1283PubMedCrossRef Anand IS, Fisher LD, Chiang YT et al (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:1278–1283PubMedCrossRef
3.
Zurück zum Zitat Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College Of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-St-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50:e1–e157PubMedCrossRef Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College Of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-St-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50:e1–e157PubMedCrossRef
4.
Zurück zum Zitat Angiolillo DJ, Biasucci LM, Liuzzo G et al (2004) Inflammation in acute coronary syndromes: mechanisms and clinical implications. Rev Esp Cardiol 57:433–446PubMedCrossRef Angiolillo DJ, Biasucci LM, Liuzzo G et al (2004) Inflammation in acute coronary syndromes: mechanisms and clinical implications. Rev Esp Cardiol 57:433–446PubMedCrossRef
5.
Zurück zum Zitat Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117:296–329PubMedCrossRef Antman EM, Hand M, Armstrong PW et al (2008) 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117:296–329PubMedCrossRef
6.
Zurück zum Zitat Antman EM, Tanasijevic MJ, Thompson B et al (1996) Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 335:1342–1349PubMedCrossRef Antman EM, Tanasijevic MJ, Thompson B et al (1996) Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 335:1342–1349PubMedCrossRef
7.
Zurück zum Zitat Apple FS, Smith SW, Pearce LA et al (2008) Use of the bioMerieux VIDAS troponin I ultra assay for the diagnosis of myocardial infarction and detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chim Acta 390:72–75PubMedCrossRef Apple FS, Smith SW, Pearce LA et al (2008) Use of the bioMerieux VIDAS troponin I ultra assay for the diagnosis of myocardial infarction and detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chim Acta 390:72–75PubMedCrossRef
8.
Zurück zum Zitat Bassan R, Tura BR, Maisel AS (2009) B-type natriuretic peptide: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department. Coron Artery Dis 20:143–149PubMedCrossRef Bassan R, Tura BR, Maisel AS (2009) B-type natriuretic peptide: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department. Coron Artery Dis 20:143–149PubMedCrossRef
9.
Zurück zum Zitat Bassand JP, Hamm CW, Ardissino D et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598–1660PubMedCrossRef Bassand JP, Hamm CW, Ardissino D et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598–1660PubMedCrossRef
10.
Zurück zum Zitat Bonaca M, Scirica B, Sabatine M et al (2010) Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol 55:2118–2124PubMedCrossRef Bonaca M, Scirica B, Sabatine M et al (2010) Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol 55:2118–2124PubMedCrossRef
11.
Zurück zum Zitat Collinson PO (1999) The need for a point of care testing: an evidence-based appraisal. Scand J Clin Lab Invest Suppl 230:67–73PubMed Collinson PO (1999) The need for a point of care testing: an evidence-based appraisal. Scand J Clin Lab Invest Suppl 230:67–73PubMed
12.
Zurück zum Zitat Danne O, Mockel M (2010) Choline in acute coronary syndrome: an emerging biomarker with implications for the integrated assessment of plaque vulnerability. Expert Rev Mol Diagn 10:159–171PubMedCrossRef Danne O, Mockel M (2010) Choline in acute coronary syndrome: an emerging biomarker with implications for the integrated assessment of plaque vulnerability. Expert Rev Mol Diagn 10:159–171PubMedCrossRef
13.
Zurück zum Zitat Danne O, Mockel M, Lueders C et al (2003) Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 91:1060–1067PubMedCrossRef Danne O, Mockel M, Lueders C et al (2003) Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 91:1060–1067PubMedCrossRef
14.
Zurück zum Zitat Diamond GA, Kaul S (2010) How would the Reverend Bayes interpret high-sensitivity troponin? Circulation 121:1172–1175PubMedCrossRef Diamond GA, Kaul S (2010) How would the Reverend Bayes interpret high-sensitivity troponin? Circulation 121:1172–1175PubMedCrossRef
15.
Zurück zum Zitat Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657–671PubMed Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657–671PubMed
16.
Zurück zum Zitat Fonarow GC, Peacock WF, Phillips CO et al (2007) Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49:1943–1950PubMedCrossRef Fonarow GC, Peacock WF, Phillips CO et al (2007) Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49:1943–1950PubMedCrossRef
17.
Zurück zum Zitat Gerber Y, McConnell JP, Jaffe AS et al (2006) Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 26:2517–2522PubMedCrossRef Gerber Y, McConnell JP, Jaffe AS et al (2006) Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 26:2517–2522PubMedCrossRef
18.
Zurück zum Zitat Giannitsis E, Becker M, Kurz K et al (2010) High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem 56:642–650PubMedCrossRef Giannitsis E, Becker M, Kurz K et al (2010) High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem 56:642–650PubMedCrossRef
19.
Zurück zum Zitat Glatz JF, Vork MM, Vusse GJ van der (1993) Significance of cytoplasmic fatty acid-binding protein for the ischemic heart. Mol Cell Biochem 123:167–173PubMedCrossRef Glatz JF, Vork MM, Vusse GJ van der (1993) Significance of cytoplasmic fatty acid-binding protein for the ischemic heart. Mol Cell Biochem 123:167–173PubMedCrossRef
20.
Zurück zum Zitat Goodman SG, Huang W, Yan AT et al (2009) The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. Am Heart J 158:193–201PubMedCrossRef Goodman SG, Huang W, Yan AT et al (2009) The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. Am Heart J 158:193–201PubMedCrossRef
21.
Zurück zum Zitat Heeschen C, Hamm CW, Mitrovic V et al (2004) N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110:3206–3212PubMedCrossRef Heeschen C, Hamm CW, Mitrovic V et al (2004) N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110:3206–3212PubMedCrossRef
22.
Zurück zum Zitat Itoi K, Jiang YQ, Iwasaki Y et al (2004) Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol 16:348–355PubMedCrossRef Itoi K, Jiang YQ, Iwasaki Y et al (2004) Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol 16:348–355PubMedCrossRef
23.
Zurück zum Zitat Jaffe AS, Ravkilde J, Roberts R et al (2000) It’s time for a change to a troponin standard. Circulation 102:1216–1220PubMed Jaffe AS, Ravkilde J, Roberts R et al (2000) It’s time for a change to a troponin standard. Circulation 102:1216–1220PubMed
24.
Zurück zum Zitat James SK, Lindahl B, Siegbahn A et al (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108:275–281PubMedCrossRef James SK, Lindahl B, Siegbahn A et al (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108:275–281PubMedCrossRef
25.
Zurück zum Zitat James SK, Lindback J, Tilly J et al (2006) Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 48:1146–1154PubMedCrossRef James SK, Lindback J, Tilly J et al (2006) Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 48:1146–1154PubMedCrossRef
26.
Zurück zum Zitat Januzzi JL Jr, Camargo CA, Anwaruddin S et al (2005) The n-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–954PubMedCrossRef Januzzi JL Jr, Camargo CA, Anwaruddin S et al (2005) The n-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948–954PubMedCrossRef
27.
Zurück zum Zitat Jernberg T, Lindahl B, Siegbahn A et al (2003) N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 42:1909–1916PubMedCrossRef Jernberg T, Lindahl B, Siegbahn A et al (2003) N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 42:1909–1916PubMedCrossRef
28.
Zurück zum Zitat Jernberg T, Stridsberg M, Venge P et al (2002) N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40:437–445PubMedCrossRef Jernberg T, Stridsberg M, Venge P et al (2002) N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40:437–445PubMedCrossRef
29.
Zurück zum Zitat Jesse RL (2010) On the relative value of an assay versus that of a test: a history of troponin for the diagnosis of myocardial infarction. J Am Coll Cardiol 55:2125–2128PubMedCrossRef Jesse RL (2010) On the relative value of an assay versus that of a test: a history of troponin for the diagnosis of myocardial infarction. J Am Coll Cardiol 55:2125–2128PubMedCrossRef
30.
Zurück zum Zitat Keller T, Tzikas S, Zeller T et al (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096–2106PubMedCrossRef Keller T, Tzikas S, Zeller T et al (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096–2106PubMedCrossRef
31.
Zurück zum Zitat Keller T, Zeller T, Peetz D et al (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361:868–877PubMedCrossRef Keller T, Zeller T, Peetz D et al (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361:868–877PubMedCrossRef
32.
Zurück zum Zitat Khan SQ, Dhillon OS, O’Brien RJ et al (2007) C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115:2103–2110PubMedCrossRef Khan SQ, Dhillon OS, O’Brien RJ et al (2007) C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115:2103–2110PubMedCrossRef
33.
Zurück zum Zitat Kolodgie FD, Burke AP, Skorija KS et al (2006) Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26:2523–2529PubMedCrossRef Kolodgie FD, Burke AP, Skorija KS et al (2006) Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26:2523–2529PubMedCrossRef
34.
Zurück zum Zitat Kurz K, Giannitsis E, Becker M et al (2011) Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome. Clin Res Cardiol 100:209–215.PubMedCrossRef Kurz K, Giannitsis E, Becker M et al (2011) Comparison of the new high sensitive cardiac troponin T with myoglobin, h-FABP and cTnT for early identification of myocardial necrosis in the acute coronary syndrome. Clin Res Cardiol 100:209–215.PubMedCrossRef
35.
Zurück zum Zitat Lee-Lewandrowski E, Corboy D, Lewandrowski K et al (2003) Implementation of a point-of-care satellite laboratory in the emergency department of an academic medical center. Impact on test turnaround time and patient emergency department length of stay. Arch Pathol Lab Med 127:456–460PubMed Lee-Lewandrowski E, Corboy D, Lewandrowski K et al (2003) Implementation of a point-of-care satellite laboratory in the emergency department of an academic medical center. Impact on test turnaround time and patient emergency department length of stay. Arch Pathol Lab Med 127:456–460PubMed
36.
Zurück zum Zitat LeLeiko RM, Vaccari CS, Sola S et al (2009) Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol 104:638–643PubMedCrossRef LeLeiko RM, Vaccari CS, Sola S et al (2009) Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol 104:638–643PubMedCrossRef
37.
Zurück zum Zitat Lemos JA de, Morrow DA, Bentley JH et al (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345:1014–1021PubMedCrossRef Lemos JA de, Morrow DA, Bentley JH et al (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345:1014–1021PubMedCrossRef
38.
Zurück zum Zitat Lindahl B, Venge P, Wallentin L (1996) Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation 93:1651–1657PubMed Lindahl B, Venge P, Wallentin L (1996) Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation 93:1651–1657PubMed
39.
Zurück zum Zitat Maisel A, Hollander JE, Guss D et al (2004) Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44:1328–1333PubMedCrossRef Maisel A, Hollander JE, Guss D et al (2004) Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44:1328–1333PubMedCrossRef
40.
Zurück zum Zitat Maisel A, Mueller C, Nowak R et al (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55:2062–2076PubMedCrossRef Maisel A, Mueller C, Nowak R et al (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55:2062–2076PubMedCrossRef
41.
Zurück zum Zitat Melanson SE, Morrow DA, Jarolim P (2007) Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol 128:282–286PubMedCrossRef Melanson SE, Morrow DA, Jarolim P (2007) Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol 128:282–286PubMedCrossRef
42.
Zurück zum Zitat Möckel M (Hrsg) (2011) Harrisons Kardiologie. ABW Wissenschaftsverlag, Berlin Möckel M (Hrsg) (2011) Harrisons Kardiologie. ABW Wissenschaftsverlag, Berlin
43.
Zurück zum Zitat Möckel M, Danne O, Lufft H et al (2003). Point of care testing (POCT) of cardiac troponin I in the emergency department in patients with acute coronary syndromes is superior to laboratory based measurements. Z Kardiol (Suppl 1) 92:198 Möckel M, Danne O, Lufft H et al (2003). Point of care testing (POCT) of cardiac troponin I in the emergency department in patients with acute coronary syndromes is superior to laboratory based measurements. Z Kardiol (Suppl 1) 92:198
44.
Zurück zum Zitat Möckel M, Müller R, Vollert JO et al (2007) Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol 96:604–612PubMedCrossRef Möckel M, Müller R, Vollert JO et al (2007) Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol 96:604–612PubMedCrossRef
45.
Zurück zum Zitat Morgenthaler NG, Struck J, Alonso C et al (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112–119PubMedCrossRef Morgenthaler NG, Struck J, Alonso C et al (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112–119PubMedCrossRef
46.
Zurück zum Zitat Morrow DA, Lemos JA de, Sabatine MS et al (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41:1264–1272PubMedCrossRef Morrow DA, Lemos JA de, Sabatine MS et al (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41:1264–1272PubMedCrossRef
47.
Zurück zum Zitat Muller-Bardorff M, Rauscher T, Kampmann M et al (1999) Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing. Clin Chem 45:1002–1008PubMed Muller-Bardorff M, Rauscher T, Kampmann M et al (1999) Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing. Clin Chem 45:1002–1008PubMed
48.
Zurück zum Zitat Newby LK, Storrow AB, Gibler WB et al (2001) Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 103:1832–1837PubMed Newby LK, Storrow AB, Gibler WB et al (2001) Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 103:1832–1837PubMed
49.
Zurück zum Zitat O’Donoghue M, Morrow DA, Sabatine MS et al (2006) Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin or atorVastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction) trial. Circulation 113:1745–1752CrossRef O’Donoghue M, Morrow DA, Sabatine MS et al (2006) Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin or atorVastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction) trial. Circulation 113:1745–1752CrossRef
50.
Zurück zum Zitat Ohman EM, Armstrong PW, Christenson RH et al (1996) Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 335:1333–1341PubMedCrossRef Ohman EM, Armstrong PW, Christenson RH et al (1996) Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 335:1333–1341PubMedCrossRef
51.
Zurück zum Zitat Oldgren J, James SK, Siegbahn A et al (2007) Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 28:699–704PubMedCrossRef Oldgren J, James SK, Siegbahn A et al (2007) Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 28:699–704PubMedCrossRef
52.
Zurück zum Zitat Omland T, Persson A, Ng L et al (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106:2913–2918PubMedCrossRef Omland T, Persson A, Ng L et al (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106:2913–2918PubMedCrossRef
53.
Zurück zum Zitat Reichlin T, Hochholzer W, Bassetti S et al (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361:858–867PubMedCrossRef Reichlin T, Hochholzer W, Bassetti S et al (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361:858–867PubMedCrossRef
54.
Zurück zum Zitat Reichlin T, Hochholzer W, Stelzig C et al (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54:60–68PubMedCrossRef Reichlin T, Hochholzer W, Stelzig C et al (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54:60–68PubMedCrossRef
55.
Zurück zum Zitat Serruys PW, Garcia-Garcia HM, Buszman P et al (2008) Effects of the direct lipoprotein-associated phospholipase A inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118:1172–1182PubMedCrossRef Serruys PW, Garcia-Garcia HM, Buszman P et al (2008) Effects of the direct lipoprotein-associated phospholipase A inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118:1172–1182PubMedCrossRef
56.
Zurück zum Zitat Sylven C, Lindahl S, Hellkvist K et al (1998) Excellent reliability of nurse-based bedside diagnosis of acute myocardial infarction by rapid dry-strip creatine kinase MB, myoglobin, and troponin T. Am Heart J 135:677–683PubMedCrossRef Sylven C, Lindahl S, Hellkvist K et al (1998) Excellent reliability of nurse-based bedside diagnosis of acute myocardial infarction by rapid dry-strip creatine kinase MB, myoglobin, and troponin T. Am Heart J 135:677–683PubMedCrossRef
57.
Zurück zum Zitat Thygesen K, Alpert JS, White HD (2007) Universal definition of myocardial infarction. Eur Heart J 28:2525–2538PubMedCrossRef Thygesen K, Alpert JS, White HD (2007) Universal definition of myocardial infarction. Eur Heart J 28:2525–2538PubMedCrossRef
58.
Zurück zum Zitat Wildner G, Prause G, Gemes G (2008) Point-of-care-testing im Notarztdienst. Notfall Rettungsmed 11:353–363CrossRef Wildner G, Prause G, Gemes G (2008) Point-of-care-testing im Notarztdienst. Notfall Rettungsmed 11:353–363CrossRef
59.
Zurück zum Zitat Wilson SR, Sabatine MS, Braunwald E et al (2009) Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. Am Heart J 158:386–391PubMedCrossRef Wilson SR, Sabatine MS, Braunwald E et al (2009) Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. Am Heart J 158:386–391PubMedCrossRef
Metadaten
Titel
Kardiale Biomarker in der Notfallmedizin
verfasst von
Prof. Dr. M. Möckel
J. Searle
O. Danne
C. Müller
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Notfall + Rettungsmedizin / Ausgabe 3/2011
Print ISSN: 1434-6222
Elektronische ISSN: 1436-0578
DOI
https://doi.org/10.1007/s10049-010-1350-7

Weitere Artikel der Ausgabe 3/2011

Notfall + Rettungsmedizin 3/2011 Zur Ausgabe

Notfall aktuell

Akuter Kopfschmerz